Diagnostic techniques and prognostic indicators

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. González-Calle V et al. Haematologica. 2017 Jan 25. pii: haematol.2016.158345. doi: 10.3324/haematol.2016.158345. [Epub ahead of print]. Capillary electrophoresis analysis of N-glycosylation changes of serum paraproteins in multiple myeloma. Kovacs Z et al. Electrophoresis. 2017 Jan 24. doi: 10.1002/elps.201700006. [Epub ahead…

Details

Related conditions

New and developing therapies for AL amyloidosis. Zumbo G et al. Expert Opin Pharmacother. 2016 Dec 29:1-11. doi: 10.1080/14656566.2016.1274971. [Epub ahead of print]. Pathological characteristics of fifty patients with renal amyloidosis in Sri Lanka Dasanayaka DL et al. Ceylon Med J. 2016 Dec 30;61(4):189-190. doi: 10.4038/cmj.v61i4.8388. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and…

Details

Emerging treatments

Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Vogl DT et al. Clin Cancer Res. 2017 Jan 4. pii: clincanres.2526.2016. doi: 10.1158/1078-0432.CCR-16-2526. [Epub ahead of print]. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137). Simões-Pires CA et al. Expert Opin Ther Pat. 2017 Jan 16. doi: 10.1080/13543776.2017.1282945.…

Details

Biology and genetics

Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. Durusu İZ et al. Leuk Res. 2017 Jan 16;55:33-40. doi: 10.1016/j.leukres.2017.01.019. [Epub ahead of print]. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Adamik J et al. Mol Cancer Res. 2017 Jan 23. pii: molcanres.0242.2016. doi: 10.1158/1541-7786.MCR-16-0242-T. [Epub ahead of print].…

Details

General

Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Kapoor P et al. Nat Rev Clin Oncol. 2017 Feb;14(2):73-74. doi: 10.1038/nrclinonc.2016.221. Epub 2017 Jan 10. Trends in overall survival and costs of multiple myeloma, 2000-2014. Fonseca R et al. Leukemia. 2017 Jan 20. doi: 10.1038/leu.2016.380. [Epub ahead of print]. Current treatment options of T cell-associated immunotherapy in multiple myeloma. Liu H et…

Details

Complications of myeloma and its treatments

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Snowden JA et al. Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14514. [Epub ahead of print]. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. Beijers AJ et al. Ann Hematol. 2017 Jan 23. doi: 10.1007/s00277-017-2927-8. [Epub ahead…

Details

Current treatments

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Durie BG et al. Lancet. 2016 Dec 22. pii: S0140-6736(16)31594-X. doi: 10.1016/S0140-6736(16)31594-X. [Epub ahead of print]. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly…

Details

EMA recommends approval of Revlimid® maintenance post-SCT for myeloma patients

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Revlimid (lenalidomide) as a maintenance treatment for newly diagnosed myeloma patients who have undergone high-dose therapy and stem cell transplantation (SCT). Revlimid is currently licensed for use in combination with dexamethasone for myeloma patients who have received…

Details